Follow up to 5 Years of a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD)

Trial Profile

Follow up to 5 Years of a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs MA09 retinal pigment epithelial cell replacement therapy-Advanced Cell Technology (Primary)
  • Indications Stargardt disease
  • Focus Adverse reactions
  • Sponsors Astellas Institute for Regenerative Medicine
  • Most Recent Events

    • 13 Jun 2017 Planned End Date changed from 1 Aug 2029 to 1 Dec 2019.
    • 13 Jun 2017 Planned primary completion date changed from 1 Aug 2029 to 1 Dec 2019.
    • 03 Jun 2016 Planned End Date changed from 1 Dec 2030 to 1 Aug 2029.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top